

**TEST CHANGE** 

Gamma Aminobutyric Acid Receptor, Type B (GABA-BR) Antibody, IgG by CBA-IFA with Reflex to Titer, CSF

3001267, GABA-B CSF

Specimen Requirements:

**Patient Preparation:** 

Collect: CSF.

Specimen Preparation: Transfer 0.5 mL CSF to an ARUP <u>standard transport</u>

tube. Standard Transport Tube. (Min: 0.15 mL)

Effective Date: August 21, 2023

Transport Temperature: Refrigerated.

Unacceptable Conditions: Hemolyzed, contaminated, or severely lipemic specimens.

Remarks:

Stability: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

Methodology: Semi-Quantitative Cell-Based Indirect Fluorescent Antibody

Performed: Wed

Reported: 1-8 days

Note: If Gamma Aminobutyric Acid Receptor, Type B (GABA-BR)

Antibody, IgG by IFA with Reflex to Titer, CSF is positive, then a Gamma Aminobutyric Acid Receptor, Type B (GABA-BR)

Antibody Titer, IgG, CSF is performed. Additional charges apply.

CPT Codes: 86255; if reflexed, add 86256

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Gamma-amino butyric acid receptor, type B (GABA-BR) antibody is found in a subset of patients with autoimmune epilepsy and other autoimmune neurologic phenotypes; it limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response, therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patients clinical history and other laboratory findings.encephalitis.

This indirect fluorescent antibody assay utilizes GABA-BR transfected cell lines for the detection and semiguantification of GABA-BR IgG antibody. semi-quantification of GABA-BR IgG antibody.



This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Effective Date: August 21, 2023

Reference Interval:		
Less than 1:1		